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Background: Glutathione S-transferase P1 1 (GSTP1) belongs to themultigene isozyme family involved in
cellular response to oxidative stress and apoptosis. Our initial retrospective proteomic analysis suggested that
GSTP1 is associated with heart failure (HF). Although proeB-type natriuretic peptide (proBNP) serves cur-
rently as a surrogate diagnostic and prognostic parameter inHF patients, its specificity remains uncertain.We
hypothesized that GSTP1 might be a useful serum marker in the monitoring of HF patients.
Methods and Results: Serum GSTP1 and proBNP were prospectively measured in 193 patients subdi-
vided based on their ejection fraction (EF) either in equal-sized quintiles or predefined EF groups
O52%, 43%e52%, 33%e42%, 23%e32% and #22%. At a cutoff of $231 ng/mL, GSTP1 identified
HF patients with EF #22% with 81% sensitivity and 83% specificity, and at a cutoff of $655 pg/mL,
proBNP identified the same patient group with 84% sensitivity and 22% specificity. GSTP1 at a $126
ng/mL cutoff identified EF #42% with 90% sensitivity and 95% specificity, or proBNP at a $396 pg/
mL cutoff had 97% sensitivity and 20% specificity. In regression analyses, GSTP1, but not proBNP, dis-
criminated between EF #42% and EF O42% in HF patients.
Conclusions: These results suggest that GSTP1 is strongly associated with HF and could serve as a sen-
sitive and specific marker to predict the ventricular function in HF patients. (J Cardiac Fail
2012;18:253e261)
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Open access under CC BY-NC-ND license.could predict ejection fraction (EF) in HF patients and
help to optimize treatment monitoring and outcome is
therefore highly desirable. Ideally, such a test should be
sensitive, specific, noninvasive, quick, and cheap. Although
a number of factors2e4 have been reported as HF bio-
markers, B-type natriuretic peptide (BNP) and its inactive
N-terminal fragment (proBNP) have gained the broadest
acceptance in diagnosis and monitoring of patients with
suspected or established HF.3,5,6 However, circulating
BNP and proBNP levels are affected by renal function
and are age and sex dependent.7,8
Glutathione S-transferase P1 1 (GSTP1) is the most prev-
alent mammalian isozyme of the glutathione S-transferase
family. GSTP1 is an important regulator of inflammation
and performs a key role in cellular homeostasis, including
inhibition of apoptosis, detoxification of reactive oxygen
species, and maintenance of the cellular redox state.9e11
Whether serum GSTP1 could monitor cardiac function in
HF patients, particularly regarding their EF, remains un-
known. We therefore addressed this issue.
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Patients
The Ethics Committee of the Medical University of Vienna
approved this study, and each of the individuals gave informed
consent to be enrolled. The study comprised two parts: first, an ini-
tial retrospective protemic analysis of serum and myocardial bi-
opsy samples obtained from HF patients undergoing heart
transplantation or heart transplant donors who served as control
subjects (Fig. 1; Table 1); and second, prospective serum analyses
of 193 HF patients. Furthermore, 20 healthy individuals who had
no history of cardiovascular diseases and had a normal EF in echo-
cardiography served as control subjects (Fig. 1, Table 1).
All HF patients underwent echocardiography, coronary artery
angiography, and right-side heart catheterization for evaluation
of ventricular function and standard hemodynamic parameters
by two independent cardiologists. Patients with malignancies
(n 5 2) and acute endocarditis (n 5 17) were excluded.
Echocardiography
All patients and control subjects underwent echocardiographic
examination including M-Mode, two-dimensional echocardiogra-
phy, and conventional and color Doppler. Left ventricular EF
was determined using the biplane Simpson method.12 PatientsFig. 1. Study design and patient groups. EF, ejection fraction; ELI-
SA, enzyme-linked immunosorbent assay; GSTP1, glutathione S-
transferase P1 1; HF, heart failure.were subdivided into 5 predefined groups (Fig. 1) based on their
left ventricular (LV) EF as follows: EF O52% (n 5 10), EF
43%e52% (n 5 30); EF 33%e42% (n 5 20), EF 23%e32%
(n 5 40), and EF #22% (n 5 93), according to the recently re-
ported risk stratification criteria.13,14 To avoid sample sizeerelated
bias, the study patients were also classified based on their EF in
equal-sized quintiles. The LV mass index (LVMI) was calculated
as described previously.15
Serum and Cardiac Tissue Collection
Peripheral venous blood was collected from end-stage HF
patients during their routine surveillance or shortly before trans-
plantation, and myocardial biopsies were obtained from the ante-
rior LV wall of their explanted hearts as previously reported.16
Serum and myocardial biopsies obtained from the anterior LV
wall were collected from heart donors during cardiac allograft im-
plantation. Serum samples were collected from HF patients with
preserved EF during their routine surveillance. All samples were
coded and snap frozen in liquid nitrogen until further use.
Serum and Cardiac Tissue Protein Array
Randomly selected serum samples from end-stage HF patients
and donors were pooled for each group. For protein array, the tis-
sue lysates from LV myocardial biopsies of explanted hearts in
transplant patients and donor control hearts were used. The protein
array was performed on an antibody Microarray 500 (Clontech,
Mountain View, California) as described elsewhere.17 The fluores-
cence was detected by a GenePix 4000B scanner (Molecular
Dynamics, Sunnyvale, California) and quantified by the Microar-
ray Analysis Workbook (http://bioinfo.clontech.com).
GSTP1 and proBNP Assays
Enzyme-linked immunosorbent assay (ELISA) for GSTP1
(Hepkit-Pi; Biotrin International, Dublin, Ireland) was performed
and quantified spectrophotometrically by an automated microplate
reader (Anthos, Salzburg, Austria). N-Terminal proBNP was mea-
sured in undiluted serum automatically by a chemiluminescent
noncompetitive ELISA (Roche Diagnostics, Mannheim, Ger-
many) on a Roche Elecsys 2010 analyzer.
Quantitative Real-Time Reverse-Transcription
Polymerase Chain Reaction
Total RNAwas isolated from LV biopsies using Trizol (Invitro-
gen, Carlsbad, California) with a Magna Lyser system (Roche).
Real-time reverse-transcription polymerase chain reaction (aver-
age value of 3 measurements) was performed on a Lightcycler in-
strument (Roche).16 The primer sequences were (sense/antisense):
GSTP1: 50-CCAAAGGTGGTGAGCTTCAT-30/50-TCTACCCAG
CATGGAGGAAC-30; and b2-microglobulin: 50-GATGAGTATG
CCTGCCGTGTG-30/50-CAATCCAAATGCGGCATCT-30. mRNA
expression levels of GSTP1 were normalized to those of b2-
microglobulin as a housekeeping gene.16
Western Blotting
GSTP1 expression was analyzed in tissue lysates by Western
blotting as described previously16 using primary monoclonal anti-
human GSTP1 antibody (Bethyl, Montgomery, Texas). Protein
bands were quantified by Imagequant software, and specific pro-
tein signals (average value of 3 measurements) were normalized
to loading control samples.
Table 1. Demographic Data, Clinical Characteristics, and the Most Heart Failure (HF)eRelevant Medication of the Study Individuals
Characteristic
Retrospective Study Prospective Study (ELISA)
Control Subjects HF Patients
Control Subjects
HF Patients
Serum Array Tissue Array Serum Array EF O42% EF #42%
n 40 20 40 20 40 153
Age (y) 47 6 11 45 6 11 54 6 8 52 6 4 55 6 11 52 6 12
Male (%) 48% 60% 55% 50% 70% 70%
DM, n (%) e e 7 (18%) e e 47 (21%)
IDDM, n (%) e e 4 (10%) e e 31 (14%)
NIDDM, n (%) e e 3 (8%) e e 16 (7%)
NYHA functional classification, n (%)
I e e e e 19 (48%)
II e e e e 18 (45%)
III e e 15 (38%) e 3 (7%) 99 (45%)
IV e e 25 (62%) e 54 (24%)
Diagnosis, n (%)
ICM e e 17 (42%) e 20 (50%) 54 (24%)
DCM e e 20 (50%) e 20 (50%) 87 (39%)
Other e e 3 (8%) e e 12 (6%)
Hemodynamic parameters
EF (%) O60 O60 22 6 6 O60 45 6 5 23 6 10
PAP (mm Hg) e e 30 6 15 e 42 6 5 32 6 10
PCWP (mm Hg) e e 21 6 11 e e 22 6 14
PVR (Wood units) e e 2.86 6 1.72 e e 2.56 6 1.52
CI (L min1 m2) e e 2.36 6 0.81 e e 2.18 6 0.72
Laboratory findings
Creatinine (mg/dL) e e 1.48 6 0.64 e 1.69 6 1.46 1.41 6 0.53
GSTP1 (ng/mL) 21 6 10 22 6 8 395 6 73 20 6 5 89 6 40 269 6 160
proBNP (pg/mL) 84 6 7 88 6 5 1,356 6 587 90 6 7 841 6 594 1,265 6 609
Medication, n (%)
ACE inhibitor e e 15 (38%) e 152 (68%)
ARB e e 8 (20%) e 49 (22%)
Beta-blocker e e 29 (73%) e 181 (82%)
Levosimendan e e 7 (18%) e 33 (15%)
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CI, cardiac index; DCM, dilated cardiomyopathy; DM, diabetes mellitus; EF,
ejection fraction; ICM, ischemic cardiomyopathy; IDDM, insulin-dependent diabetes mellitus; NIDDM, noninsulin-dependent diabetes mellitus; PAP, pul-
monary artery pressure; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance.
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Paraffin sections of cardiac biopsies obtained from the
explanted hearts of HF patients (n 5 6) undergoing cardiac trans-
plantation or those obtained from donated hearts during allograft
implantation (n 5 4) were blocked with phosphate-buffered saline
solution supplemented with 5% goat serum and stained with
a monoclonal antihuman GSTP1 antibody (Bethyl). The primary
antibody was detected by sequential incubation with Alexa Fluor
488econjugated secondary antibody (Invitrogen). Slides were
then counterstained with 0.1 mg/mL 4,6-diamidino-2-
phenylindole (DAPI; Molecular Probes, Eugene, Oregon) and
analyzed under a fluorescence microscope.
Statistical Analysis
GSTP1 and proBNP serum concentrations were compared be-
tween patient groups by 1-way analysis of variance (ANOVA)
and post hoc Tukey test according to the scale of the variable.
In case of skewed data, a nonparametric test (Mann-Whitney U
test) or 1-way ANOVA with Tukey test accomplished with log
transformation was used. To investigate the relationship between
GSTP1 and proBNP, as well as the relationship of GSTP1 to
age, pulmonary artery pressure (PAP), pulmonary capillary wedge
pressure (PCWP), pulmonary vascular resistance (PVR), cardiac
index (CI), and creatinine, Spearman rank correlation coefficients
(rS) were computed. The differences between the correlationswere tested with t test for GSTP1 and proBNP with EF, or Fischer
transformationfor GSTP1 with proBNP. The corresponding re-
ceiver operating characteristic curve (ROC) analyses were used
to find optimal cutoff levels for GSTP and proBNP as the values
that minimize the distance between the ROC curve and the upper
left corner of the panel. The area under the ROC curve (AUC) of
GSTP1 and proBNP for cutoff points were compared by the De-
Long and DeLong method and by the Pencina method expressed
as net reclassification improvement (NRI) and integrated discrim-
ination improvement (IDI). Sensitivity and specificity of GSTP1
and proBNP cutoffs were calculated by table analysis and com-
pared by McNemar test. Univariate and multivariate logistic re-
gression was used to assess the ability of GSTP1, proBNP,
LVMI, age, PCWP, PVR, CI, and creatinine to predict LV function
assessed by EF. For logistic regression analysis, EF was consid-
ered as a dichotomous variable at a cutoff level of 42%. All statis-
tical analyses were performed using SAS system for Windows,
version 9.1.3, and Enterprise Guide, version 4.1 (SAS Institute,
Cary, North Carolina). Statistical significance was set at
P ! .05. Results are expressed as mean 6 SD.
Results
GSTP1 Is Associated with HF
The screening array identified GSTP1 to be a protein asso-
ciated with HF and that its serum levels are increased in HF
256 Journal of Cardiac Failure Vol. 18 No. 3 March 2012patients comparedwith control donors (Fig. 2A). ELISA anal-
yses verified the array findings and indicated that serum
GSTP1 concentrations were significantly increased in end-
stage HF patients compared to controls (P! .001; Fig. 2B).
The tissue protein array in the same patient cohort indicated
elevated GSTP1 expression levels in myocardium of end-
stage HF patients compared with control subjects (Fig. 2C).
These findings were confirmed by immunohistochemistry
and Western blot analyses (P! .001; Fig. 2D and 2E).
GSTP1 Correlates with EF in HF
Serum GSTP1 concentrations were significantly higher
in patients with EF #22% compared with all other EF
groups (P ! .0001), and HF patients with EF 23%e32%
had significantly higher GSTP1 serum concentrations com-
pared with those with EF 43%e52% orO52% (P! .0001;
Fig. 3A). However, serum proBNP concentrations were sig-
nificantly higher only in patients with EF #22% compared
with other groups (P! .0001; Fig. 3B). When using equal-
sized quintiles, serum GSTP1 concentrations were still sig-
nificantly different among quintiles (P ! .0001), with theFig. 2. Serum and cardiac glutathione S-transferase P1 1 (GSTP1) asso
array images demonstrate enhanced staining for serum GSTP1 protei
Enzyme-linked immunosorbent assay (ELISA) indicates elevation of se
onstrate enhanced cardiac tissue GSTP1 signals in HF patients. (D) We
*P ! .001. (E) Immunohistochemistry indicates higher expression of Ghigher concentrations belonging to patients with lower EF
(Fig. 3C). In contrast, serum proBNP concentrations were
significantly lower only in patients with EF O45% com-
pared with EF!45% (P! .0001; Fig. 3D). Overall, serum
GSTP1 concentrations correlated more significantly
(rS 5 0.82; P ! .0001) with EF than serum proBNP
did (rS 5 0.37; P! .0001; Table 2; Fig. 4). Considering
EF as a dichotomous variable based on a cutoff level of
42% suggested that serum GSTP1 concentrations still cor-
related significantly with EF in patients with EF O42%
(rS 5 0.20; P 5 .05) and in those with EF #42%
(rS 5 0.64, P! .0001); whereas proBNP serum concen-
trations did not (Table 2; Fig. 4).
Serum GSTP1 Is an Independent Predictor of EF in HF
Univariate logistic regression analyses demonstrated that
GSTP1 significantly discriminates between HF patients
with EF O42% and those with EF !42% (odds ratio
[OR] 0.98; P! .001; Table 3). Also, GSTP1 discriminated
patients with EF O22% (OR 0.98; P ! .0001; Table 3).
The subsequent multivariate logistic regression analysesciation with heart failure (HF). (A) Representative serum protein
n in end-stage HF patients compared with control subjects. (B)
rum GSTP1 in HF patients. *P ! .0001. (C) Array images dem-
stern blotting indicates elevation of GSTP1 protein in HF patients.
STP1 in cardiac tissue of HF patients.
Fig. 3. Serum cardiac glutathione S-transferase P1 1 (GSTP1) and
proeB-type natriuretic peptide (proBNP) association with ejection
fraction (EF). Patients are divided into relative arbitrary groups
(A, B) and equal-sized quintiles (C, D). (A) HF patients with
EF #22% have significantly higher serum GSTP1 concentrations
compared with all other EF groups. Patients with EF 23%e32%
and EF #22% have significantly higher serum GSTP1 concentra-
tion compared with those with EF 43%e52% and EFO52%. (B)
Patients with EF #22% have significantly higher serum proBNP
concentration compared with all other EF groups. (C) Serum
GSTP1 concentrations are significantly different among EF quin-
tiles, and higher GSTP1 concentrations are associated with low
EF. (D) Serum proBNP concentrations are significantly lower in
patients with EF O45% compared with other quintiles.
*P ! .0001 vs all groups; yP ! .0001 vs EF 43%e52% and
EF O52%; zP ! .0001 vs all groups.
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dicted LV function in HF patients with EF O42% (OR
0.98; P ! .002) and EF O22% (OR 0.99; P ! .0001;
Table 3); pro-BNP was not associated with such predictive
abilities (Table 3).
In concert with these findings, ROC curve analyses sug-
gested that GSTP1 at an optimal cutoff level of O126 ng/
mL diagnosed HF patients with EF!42% with a 90% sensi-
tivity and a 95% specificity (AUC 0.95; P! .0001), whereas
proBNPat an optimal cutoff level ofO396pg/mL(AUC0.62;P ! .01) identified EF !42% with a 97% sensitivity and
a 20% specificity (Fig. 5A). Furthermore, at an optimal cutoff
level of O231 ng/mL GSTP1 diagnosed EF !22% (AUC
0.89;P! .0001; Fig. 5B)with a sensitivity of 81%anda spec-
ificity of 83%. In comparison, serum proBNP at an optimal
cutoff level of O655 pg/mL diagnosed EF !22% (AUC
0.56; P5 .07; Fig. 5B) with a sensitivity of 84% and a speci-
ficity of 22%. InMcNemar test, proBNPwasmore sensitive to
diagnose both EF !42% and EF !22%; however, GSTP1
had a higher specificity (P! .001; Table 4). Comparison of
the AUC of both GSTP1 and proBNP indicated GSTP1 to
be superior in diagnosing both EF !42% (AUC difference
0.34, confidence interval [CI] 0.23e0.45; P ! .0001) and
EF !22% (AUC difference 0.33, CI 0.24e0.41;
P! .0001; Table 4). Additionally, Pencina analysis revealed
significantly different NRI and IDI for serum GSTP1 AUCs
(P ! .001; Table 4). These results indicated GSTP1 to be
an independent, sensitive, and specific predictor of LV func-
tion in HF.
Association of GSTP1 and proBNP with NYHA
Classification
Both serum GSTP1 and proBNP concentrations were
significantly increased in New York Heart Association
(NYHA) functional class III and IV compared with
NYHA II patients (P ! .0001; Fig. 6A and 6B), although
serum GSTP1 and proBNP were not significantly different
when NYHA III and IV patients were compared. In addi-
tion, we found significantly higher EF values in NYHA II
compared with NYHA III and IV patients (P! .0001), al-
though EF was not significantly different between NYHA
III and IV patients (Fig. 6C).
Correlation of GSTP1 and proBNP with Demographic
and Clinical Parameters
Serum GSTP1 correlated significantly but only weakly
with patient age (rS 5 0.26; P ! .001), PCWP (rS 5
0.32; P 5 .05), and CI (rS 5 0.45; P ! .001; Table 2).
In addition, LVMI showed a significant correlation with
proBNP but not GSTP1 in all patients (rS 5 0.16; P 5
.04). A significant but not strong correlation was observed
between serum GSTP1 and creatinine in patients with EF
!42% (rS 5 0.24; P 5 .005; Table 2). A significant corre-
lation was also present between GSTP1 and proBNP in the
entire study cohort (rS 5 0.36; P ! .0001) and in patients
with EF O42% (rS 5 0.34; P ! .03; Table 2; Fig. 7).
Discussion
ProBNP is currently accepted to be a surrogate parameter
in HF monitoring, yet existing data indicate divergent
results.2e8 Our purpose was therefore to find a serum
marker that allows monitoring of ventricular function in
HF patients. Our screening suggested that GSTP1 is associ-
ated with end-stage HF. GSTP1 belongs to the multigene
family of isozymes important for detoxification and xenobi-
otic mechanisms9 and determination of the cellular
Table 2. Spearman Correlation Analysis Between Glutathione S-Transferase P1 1 (GSTP1) and proeB-Type Natriuretic Peptide
(proBNP) and Clinical Variables of Study Patients (rS, Values)
Covariate
All patients EF O42% EF #42%
GSTP1 proBNP GSTP1 proBNP GSTP1 proBNP
GSTP1 ng/mL e 0.36, !.0001 e 0.34,5.03 e 0.087, .29
EF 0.82, !.0001 0.37, !.0001 0.20, .05 0.24, .41 0.64, !.0001 0.08, .32
Age (y) 0.26, !.001 0.1, .22 0.04, .91 0.14, .68 0.30, !.001 0.15, .021
PCWP (mm Hg) 0.32, .05 0.04, .63 0.18, .97 0.09, .63 0.041, .63 0.065, .44
PVR (Wood units) 0.091, .62 0.06, .82 0.02, .73 0.18, .56 0.1, .27 0.07, .4
CI (L min1 m2) 0.45, !.001 0.21, .41 0.03, .68 0.14, .81 0.05, .63 0.15, .14
Creatinine (mg/dL) 0.13, .11 0.12, .14 0.073, .83 0.52, .10 0.24,!.005 0.01, .93
LVMI 0.10, .43 0.16, .04 0.21, .31 0.57, !.0001 0.082, .34 0.41, !.0001
CI, cardiac index; EF, ejection fraction; LVMI, left ventricular mass index; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure;
PVR, pulmonary vascular resistance.
Fig. 4. Correlation of (A) glutathione S-transferase P1 1 (GSTP1) and (B) proeB-type natriuretic peptide (proBNP) with ejection fraction
(EF), indicating a higher significant negative correlation of EF with serum GSTP1 compared with proBNP for all study patients. Consid-
ering EF as a dichotomous variable at a cutoff level of 42%, serum GSTP1 concentrations still significantly correlated with EF in both
resulting subgroups, whereas proBNP did not.
Table 3. Logistic Regression Analysis of Covariates That Could Predict EF O42% or EF O22%
HF Patients with EF O42% HF Patients with EF O22%
OR (95% CI) P Value OR (95% CI) P Value
Univariate log. regression
GSTP1 0.98 (0.97e0.99) .001 0.98 (0.98e0.99) .0001
proBNP 0.99 (0.997e1) .01 0.99 (0.99e1) .03
LVMI 0.98 (0.93e1.03) .38 0.99 (0.098e0.99) .03
Age 1.02 (0.96e1.08) .54 1.04 (1.01e1.08) .006
PCWP 0.99 (0.97e1.02) .32 0.98 (0.94e1.02) .35
PVR 0.94 (0.71e1.25) .12 1.08 (0.8e1.4) .62
CI 1.1 (1.001e2.53) .06 1.02 (0.5e1.9) .96
Creatinine 1.31 (0.81e2.13) .27 1.74 (0.9e3.4) .1
Multivariate log. regression
GSTP1 0.98 (0.97e0.99) .002 0.99 (0.98e0.99) .0001
ProBNP 0.99 (0.99e1) .02 1 (0.99e1.001) .94
LVMI e e 0.99 (0.99e1.02) .06
Age e e 1.04 (0.98e1.2) .18
CI, confidence interval; OR, odds ratio; other abbreviations as in Tables 1 and 2.
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Fig. 5. The power of serum glutathione S-transferase P1 1
(GSTP1) and proeB-type natriuretic peptide (proBNP) to diag-
nose ejection fraction (EF). (A) At the optimal cutoff levels of
$126 ng/mL GSTP1, with a sensitivity of 90% and specificity
of 95%, and $396 pg/mL proBNP, with a sensitivity of 97%
and specificity of 20%, identify EF #42%. (B) At $231 ng/mL
cutoff level, GSTP1 identifies EF #22% with a sensitivity of
81% and specificity of 83%, whereas proBNP at$655 pg/mL cut-
off level identifies EF #22% with a sensitivity of 84% and spec-
ificity of 22%.
GSTP-1 and Heart Failure  Andrukhova et al 259response to oxidative stress.10 Serum GSTP1 concentra-
tions diagnosed HF with significant association with EF in-
dependently from demographic and clinical characteristics
in our patient cohort. Of note, serum GSTP1 showed better
diagnostic power in HF patients with EF #42% and EF
#22% compared with proBNP, although elevated serum
GSTP1 and proBNP both were associated with NYHA
functional class III and IV.
It is well established that EF is a determinant of cardiac
risk in HF patients. The hazard ratio for all-cause mortality
increases by 39% for every 10% reduction in the EF below45%.13,14 However, HF clinical features can occur in pa-
tients with EF O45%.18 Therefore, our finding that
GSTP1 is able to discriminate HF patients with EF O42%
might be of important diagnostic and prognostic signifi-
cance. Although, proBNP is an established tool for HF diag-
nosis,19 the greatest clinical utility of proBNP is the
monitoring of HF-related hemodynamic decompensation
and disease progression rather than LV function and
EF.20,21 On the other hand, proBNP is recommended to be
mainly used for exclusion of HF with normal EF in patients
with symptoms attributed to HF.22 However, given that gen-
der and older age are associated with higher proBNP levels,7
the proposed diagnostic properties of proBNP18 might be too
unspecific to serve as a predictor for LV function.
Reportedly, proBNP can predict EF!30% with a sensi-
tivity and specificity of 90% and 71%, respectively in an
HF population with EF !45%.20 Plasma proBNP detected
EF!28% with 77% sensitivity and 69% specificity in a co-
hort of patients with EF !50%,22 and others23 found that
proBNP can predict EF !40% with an AUC of 0.69. In
the present study, proBNP had 97% sensitivity and 20%
specificity to diagnose EF O42% and 84% sensitivity and
22% specificity to diagnose EF O22%. We had no exclu-
sion criteria for EF, which could have influenced the test
characteristics regarding proBNP, which has previously
been shown to vary in HF patients with higher EF.18 This
fact could also be considered as an explanation for overall
lower specificity of proBNP compared with GSTP1 to pre-
dict LV function in HF patients.
The reason for serum GSTP1 rising in HF patients is
unclear. However, evidence is accumulating that GSTP1
participates in regulation of stress signaling and protects
cells against apoptosis via its noncatalytic ligand-binding
activity. Specifically, GSTP1 can act as an endogenous in-
hibitor of c-Jun N-terminal kinase by interaction with its
C-terminal end.24 Additionally, GSTP1 expression rises in
response to oxidative stress or proinflammatory stimuli.10
Dramatic elevations of reactive oxygen species are reported
in HF by hypertrophy and proinflammatory stimuli, indicat-
ing multiple cellular responses, such as DNA synthesis,
transcription factor activation, and gene and protein expres-
sion alteration, in HF.25 These reasons may also explain
why GSTP1 was an overall better predictor of LV function
in HF than proBNP, because inflammatory processes in HF
(associated with GSTP1) are likely to involve the entire
myocardium independently of LVMI and atrial dilation,
processes that evidently affect proBNP production. Based
on our findings, the likely mechanism that accounts for
both cardiac tissue and serum GSTP1 elevation could be
prompted by oxidative stress and inflammatory stimuli26
activated in HF.Study Limitations and Clinical Implications
The single-center nature of this study, although prospec-
tive, is a limitation. In addition, although patients with
acute endocarditis and malignancies were excluded, this
Table 4. Comparison Between Glutathione S-Transferase P1 1 (GSTP1) and proeB-Type Natriuretic Peptide (proBNP) Sensitivity,
Specificity, and Area Under the Receiver Operating Characteristic Curve (AUC) Identified for ejection fraction (EF) #22% and EF
#42% HF Patients
EF #22% EF #42%
proBNP, 655 pg/mL GSTP1, 231 ng/mL P Value proBNP, 396 pg/mL GSTP1 126 ng/mL P Value
Sensitivity, %* 84 81 !.001 97 90 !.001
Specificity, %* 22 83 !.001 20 95 !.001
AUCy 0.56 0.89 !.0001 0.62 0.95 !.0001
NRI, %z Reference 47.5 !.001 Reference 57.8 !.001
IDI, %z Reference 34.3 !.001 Reference 34.4 !.001
IDI, integrated discrimination improvement; NRI, net reclassification improvement.
*Values were compared by McNemar test.
yValues were compared by de Long and de Long test.
zValues were compared by Pencina test.
260 Journal of Cardiac Failure Vol. 18 No. 3 March 2012study can not account for the impact of potential inflamma-
tory stimuli on GSTP1 in patients before HF diagnosis, par-
ticularly in idiopathic dilated cardiomyopathy. Also, serial
measurement in an HF patient cohort might be necessary
to comparatively analyze the power of GSTP1 versus
proBNP in assessing or predicting LV function. In contrast
to these limitations, the noninvasive nature and ease of the
suggested GSTP1 serum quantification protocol, along withFig. 6. Serum (A) glutathione S-transferase P1 1 (GSTP1) and (B)
proeB-type natriuretic peptide (proBNP) and (C) ejection fraction
(EF) association with NYHA classification. Serum GSTP1 and
proBNP concentrations were significantly higher in patients with
NYHA functional class III and IV compared with those with
NYHA II. *P ! .0001 vs NYHA II.
Fig. 7. Correlation plot of serum glutathione S-transferase P1 1
(GSTP1) and proeB-type natriuretic peptide (proBNP) for all
study subjects. A significant positive correlation was observed be-
tween GSTP1 and proBNP for all study patients. Moreover, signif-
icant correlation was still present in patients with ejection fraction
(EF) O42% but not in those with EF !42%. HF, heart failure.the availability and low costs of ELISA, and finally the high
sensitivity and specificity of GSTP1, make it an attractive
serum marker to predict LV function in HF patients.
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